In their two sequential phase 1 clinical trials (NCT02395250; NCT03146234), Shi et al. reported the safety and anti-tumor activity of GPC3 CAR-T cells in GPC3+ HCC patients [47]. The gene discussed is GPC3; the disease is neoplasm.